Summary
Stryker Corporation's 2021 10-K filing reveals a strong recovery and growth trajectory following the disruptions of 2020. The company reported a 19.2% increase in net sales, reaching $17.1 billion, with organic growth of 13.4% driven by increased unit volume across most product lines. The company's strategic focus on key segments like MedSurg and Neurotechnology, and Orthopaedics and Spine, has yielded positive results. Significant growth was observed in the Orthopaedics and Spine segment, up 26.0%, indicating a robust rebound in elective procedures. Stryker continues to invest in innovation and acquisitions, with the notable pending acquisition of Vocera Communications, Inc. for approximately $3.1 billion, aiming to further enhance its market position and service offerings.
Financial Highlights
52 data points| Revenue | $17.11B |
| Cost of Revenue | $6.14B |
| Gross Profit | $10.97B |
| R&D Expenses | $1.24B |
| SG&A Expenses | $6.43B |
| Operating Expenses | $8.38B |
| Operating Income | $2.58B |
| Interest Expense | $337.00M |
| Net Income | $1.99B |
| EPS (Basic) | $5.29 |
| EPS (Diluted) | $5.21 |
| Shares Outstanding (Basic) | 377.00M |
| Shares Outstanding (Diluted) | 382.30M |
Key Highlights
- 1Stryker reported a 19.2% increase in net sales to $17.1 billion in 2021, signaling a strong recovery from the previous year.
- 2Organic sales growth was robust at 13.4%, primarily driven by an increase in unit volume across all product lines.
- 3The Orthopaedics and Spine segment experienced significant growth of 26.0%, indicating a rebound in demand for elective procedures.
- 4Stryker announced its intention to acquire Vocera Communications, Inc. for approximately $3.1 billion, expanding its digital care coordination and communication capabilities.
- 5The company maintained strong financial health, with net cash provided by operating activities of $3.26 billion.
- 6Gross profit as a percentage of net sales improved to 64.1% in 2021 from 63.1% in 2020, driven by higher volumes and favorable product mix.
- 7Research, development, and engineering expenses increased to 7.2% of net sales, reflecting continued investment in innovation.